Reaction Steps
Using general procedure E, 3-{4-[2-(4-methanesulfonyl-phenyl)-benzo[1,3]dioxol-2-yl]-piperidin-1-yl}-butylamine (see EXAMPLE 273) (139 mg, 0.32 mmol) and 2,4-dimethylnicotinic acid (53 mg, 0.35 mmol) afforded COMPOUND 274 as a white solid (59 mg, 32%). 1H NMR (CDCl3) δ 0.84-1.19 (m, 2H), 0.95 (d, 3H, J=6.6 Hz), 1.45-1.62 (m, 3H), 1.66-1.79 (m, 1H), 1.89-1.99 (m, 2H), 2.31 (s, 3H), 2.36 (t, 1H, J=11.7 Hz), 2.54 (s, 3H), 2.68-2.81 (m, 3H), 3.02 (s, 3H), 3.26-3.34 (m, 1H), 3.49 (s, 2H), 3.80-3.89 (m, 1H), 6.78-6.88 (m, 3H), 7.00 (d, 1H, J=4.8 Hz), 7.60 (d, 2H, J=8.1 Hz), 7.91 (d, 2H, J=7.8 Hz), 8.05 (br s, 1H), 8.42 (d, 1H, J=4.8 Hz). 13C NMR (CDCl3) δ 13.58, 19.20, 22.67, 25.88, 26.50, 31.68, 40.00, 44.24, 44.80, 45.65, 52.34, 60.55, 109.09, 117.67, 122.11, 122.92, 127.29, 127.63, 134.00, 141.22, 144.09, 146.41, 147.20, 149.23, 154.55, 168.70. ES-MS m/z 564 (M+H). Anal. Calcd. for C31H37N3O5S.1.0CH2Cl2.0.3H2O: C, 58.77; H, 6.10; N, 6.42. Found: C, 58.42; H, 5.79; N, 6.37.
